Abstract:BACKGROUND: Mitochondrial dynamics play a critical role in mitochondrial function. The mitofusin 2 (MFN2) gene encodes a mitochondrial membrane protein that participates in mitochondrial fusion to maintain and operate the mitochondrial network. Moreover, MFN2 is essential for mitophagy. In Ang II-induced cardiac remodeling, the combined effects of MFN2-mediated mitochondrial fusion and mitophagy are unclear. This study was designed to explore a novel strategy for preventing cardiomyocyte injury via modulation of mitochondrial dynamics.METHODS: We studied the function of MFN2 in mitochondrial fusion and mitophagy in Ang II-stimulated cardiomyocyte injury. Cardiomyocyte injury experiments, including reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP), and apoptosis rate of cardiomyocytes were performed. The mitochondrial morphology in cardiomyocytes was examined via transmission electron microscopy (TEM) and confocal microscopy. Autophagic levels in response to Ang II were examined by immunoblotting of autophagy-related proteins. Moreover, PINK1/MFN2/Parkin pathway-related proteins were examined.RESULTS: With stimulation by Ang II, MFN2 expression was progressively reduced. MFN2 deficiency impaired mitochondrial quality, resulting in exacerbated mitochondrial damage induced by Ang II. The Ang II-induced increases in ROS production and apoptosis rate were alleviated by MFN2 overexpression. Moreover, MFN2 alleviated the Ang II-induced reduction in MMP. MFN2 promoted mitochondrial fusion, and MFN2 promoted Parkin translocation and phosphorylation, leading to mitochondrial autophagy. The effects of MFN2 overexpression were reversed by autophagy inhibitors.CONCLUSION: Mitofusin 2 promotes Parkin translocation and phosphorylation, leading to mitophagy to clear damaged mitochondria. However, the beneficial effects of MFN2 were reversed by autophagy inhibitors. Additionally, MFN2 participates in mitochondrial fusion to maintain mitochondrial quality. Thus, MFN2 participated in mitophagy and mitochondrial fusion against Ang II-induced cardiomyocyte injury.

Mitofusin 2-Deficiency Suppresses Cell Proliferation Through Disturbance of Autophagy.

Mitofusin-2: A New Mediator of Pathological Cell Proliferation

Mitofusin2 Promotes Β Cell Maturation from Mouse Embryonic Stem Cells Via Sirt3/Idh2 Activation

Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway

MFN2 Suppresses Cancer Progression Through Inhibition of Mtorc2/akt Signaling.

Mir-106b-Mediated Mfn2 Suppression is Critical for Pkm2 Induced Mitochondrial Fusion

P2.01-082 Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma

[Mitochondrial Fusion Protein Mfn2 and Cardiovascular Diseases].

MFN2 Deficiency Impairs Mitochondrial Functions and PPAR Pathway During Spermatogenesis and Meiosis in Mice

Inhibition Of Mitochondrial Complex Ii Induces Mitophagy And Attenuates Cell Proliferation

Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells

Mitofusin-2 is a Major Determinant of Oxidative Stress-mediated Heart Muscle Cell Apoptosis

Mitofusin 1 and 2 Regulation of Mitochondrial DNA Content is a Critical Determinant of Glucose Homeostasis

Mitofusin 2 Triggers Vascular Smooth Muscle Cell Apoptosis Via Mitochondrial Death Pathway

Mitofusin-2 is a Novel Direct Target of P53.

Mitofusin 2 Regulates the Oocytes Development and Quality by Modulating Meiosis and Mitochondrial Function

Mitofusin-2 Prevents Skeletal Muscle Wasting in Cancer Cachexia.

Targeting Mitochondrial Dynamics by Regulating Mfn2 for Therapeutic Intervention in Diabetic Cardiomyopathy

Mitofusin 2 Participates in Mitophagy and Mitochondrial Fusion Against Angiotensin II-Induced Cardiomyocyte Injury

Transcriptional Profiling Revealed the Anti-Proliferative Effect of MFN2 Deficiency and Identified Risk Factors in Lung Adenocarcinoma

MFN2 suppresses the accumulation of lipid droplets and the progression of clear cell renal cell carcinoma